GlassScriptPhysician profile
Anat Galor
NPI 1962452813
$70,198.89
in general payments reported to CMS, 2019-2025
28 companies · $8,230 in 2025
The $8,230 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,257 · 2020: $1,658 · 2021: $15K · 2022: $4,168 · 2023: $18K · 2024: $22K · 2025: $8,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Food and Beverage: $4,592 · Honoraria: $741 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,725.00 |
| Food and Beverage | $4,592.09 |
| Honoraria | $741.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $22,924.64 | 2019-2025 | Oxervate |
| Alcon Research LLC | $12,500.00 | 2024-2025 | |
| Ocular Therapeutix, INC. | $7,800.00 | 2021 | |
| Alcon Vision LLC | $5,770.92 | 2019-2025 | Clareon, Tryptyr |
| Abbvie INC. | $3,188.79 | 2022-2025 | |
| Oyster Point Pharma, INC. | $2,195.21 | 2022-2023 | Tyrvaya |
| Astrazeneca Uk Limited | $2,148.00 | 2022 | |
| Horizon Therapeutics Plc | $2,043.37 | 2021 | |
| Heidelberg Engineering, INC. | $2,000.00 | 2021-2023 | Spectralis |
| Janssen Research & Development, LLC | $1,700.00 | 2025 | |
| Daiichi Sankyo INC. | $1,611.00 | 2021 | |
| Allergan, INC. | $1,159.31 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $877.28 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $782.42 | 2019-2022 | |
| Thea Pharma INC. | $719.63 | 2022-2025 | Iyuzeh |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $701.00 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $455.77 | 2020-2025 | Acthar |
| Quidel Corporation | $388.57 | 2019-2022 | |
| Biogen, INC. | $360.00 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $253.79 | 2021-2023 | Amo Phaco Needle |
| Eyepoint US, INC. | $122.58 | 2022 | |
| Shire North American Group INC | $122.29 | 2019 | |
| Mallinckrodt Enterprises LLC | $112.80 | 2019 | |
| Tearlab Corp | $97.17 | 2024 | Scoutpro Osmolarity System |
| Sun Pharmaceutical Industries INC. | $86.84 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $19.96 | 2025 | Xdemvy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anat Galor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.